MA27133A1 - Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe - Google Patents

Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe

Info

Publication number
MA27133A1
MA27133A1 MA27517A MA27517A MA27133A1 MA 27133 A1 MA27133 A1 MA 27133A1 MA 27517 A MA27517 A MA 27517A MA 27517 A MA27517 A MA 27517A MA 27133 A1 MA27133 A1 MA 27133A1
Authority
MA
Morocco
Prior art keywords
lercanidipine hydrochloride
manufacturing process
polymorphic forms
new crystalline
crystalline polymorphic
Prior art date
Application number
MA27517A
Other languages
English (en)
Inventor
Fausto Bonifacio
Francesco Campana
Iasi Gianluca De
Amedeo Leonardi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of MA27133A1 publication Critical patent/MA27133A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

NOUVELLES FORMES BRUTES ET CRISTALLINES DU CHLORHYDRATE DE LERCANIDIPINE L'invention décrit de nouvelles Formes brutes (A) et (B) de la lercanidipine, de nouvelles Formes cristallines (I) et (II) du chlorhydrate de lercanidipine obtenues à partir desdites Formes brutes, des compositions pharmaceutiques antihypertensives contenant en tant qu'un agent actif au 10 moins l'une des Formes cristallines (I) et (II) du chlorhydrate de lercanidipine, et des méthodes pour leur utilisation.
MA27517A 2001-08-06 2004-02-06 Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe MA27133A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001726A ITMI20011726A1 (it) 2001-08-06 2001-08-06 Forme polimorfe della lercanidipina cloridrato

Publications (1)

Publication Number Publication Date
MA27133A1 true MA27133A1 (fr) 2005-01-03

Family

ID=11448245

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27517A MA27133A1 (fr) 2001-08-06 2004-02-06 Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe

Country Status (36)

Country Link
EP (4) EP1600441B1 (fr)
JP (1) JP2005504045A (fr)
KR (3) KR20050043992A (fr)
CN (2) CN100448847C (fr)
AP (1) AP1766A (fr)
AR (1) AR037139A1 (fr)
AT (2) ATE453624T1 (fr)
AU (1) AU2002327924C1 (fr)
BR (1) BR0211739A (fr)
CY (2) CY1109711T1 (fr)
DE (2) DE60206787T2 (fr)
DK (3) DK1600441T3 (fr)
EA (1) EA005673B1 (fr)
EC (1) ECSP044973A (fr)
ES (3) ES2334678T3 (fr)
HK (3) HK1067123A1 (fr)
HR (1) HRP20040156B1 (fr)
HU (1) HU229563B1 (fr)
IL (3) IL164648A0 (fr)
IT (1) ITMI20011726A1 (fr)
MA (1) MA27133A1 (fr)
ME (2) MEP2908A (fr)
MX (1) MXPA04001069A (fr)
NO (2) NO325541B1 (fr)
NZ (2) NZ541341A (fr)
OA (1) OA12648A (fr)
PE (1) PE20030328A1 (fr)
PL (1) PL216066B1 (fr)
PT (2) PT2157083E (fr)
RS (1) RS52161B (fr)
SI (3) SI1600441T1 (fr)
TN (1) TNSN04024A1 (fr)
UA (1) UA82988C2 (fr)
UY (1) UY27410A1 (fr)
WO (1) WO2003014084A1 (fr)
ZA (1) ZA200401806B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
DE04801160T1 (de) * 2003-12-01 2007-08-09 Lifecycle Pharma A/S Pharmazeutische zusammensetzungen mit lercanidipin
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
KR100821165B1 (ko) * 2006-03-10 2008-04-14 동우신테크 주식회사 레르카니디핀 염산염의 제조 방법
EP2114883A4 (fr) * 2006-12-29 2010-09-08 Dongwoo Syntech Co Ltd Procédé de préparation de chlorhydrate de lercanidipine
EP2121575A2 (fr) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Polymorphes de chlorhydrate de lercanidipine et procede ameliore de preparation d'acetoacetate de 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyle
EP2585051B2 (fr) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Formes pharmaceutiques à usage oral comprenant de la lercanidipine et de l'énalapril et leurs sels pharmaceutiquement acceptables
EP2444394A1 (fr) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Procédé de préparation de forme amorphe de lercanidipine HCI
EP2654729B1 (fr) 2010-12-24 2016-05-04 KRKA, d.d., Novo mesto Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables ainsi qu'un acide organique
JP2014511867A (ja) * 2011-04-18 2014-05-19 合肥貝霓医薬科技有限公司 ジヒドロピリジン系カルシウムチャネルブロッカーの精製、及びそのナノ粒子の調製方法
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102584682A (zh) * 2011-12-31 2012-07-18 苏州二叶制药有限公司 盐酸乐卡地平的制备方法
CN103497075B (zh) * 2013-09-25 2016-03-23 山西北化关铝化工有限公司 水悬浮延期药造型粉
CN109232389B (zh) * 2018-05-15 2021-10-08 迪嘉药业集团有限公司 一种小粒度硝苯地平的结晶制备方法
CN115353485B (zh) * 2022-07-26 2024-04-19 山西双雁药业有限公司 从硝苯地平母液中回收硝苯地平的方法及应用
CN115671066B (zh) * 2022-11-21 2024-07-02 安徽宏业药业有限公司 一种盐酸乐卡地平片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596139A (en) * 1897-12-28 Process of generating acetylene gas
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
KR20030031886A (ko) 2000-02-16 2003-04-23 뉴로젠 코포레이션 치환된 아릴피라진
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
ITMI20011726A1 (it) 2003-02-06
RS52161B (en) 2012-08-31
NO20040266L (no) 2004-03-24
EP2157083A2 (fr) 2010-02-24
IL164648A0 (en) 2005-12-18
RS11304A (en) 2007-02-05
KR20040030903A (ko) 2004-04-09
DE60206787D1 (de) 2006-03-02
KR100626819B1 (ko) 2006-09-20
DK1432683T3 (da) 2006-03-06
ZA200401806B (en) 2005-06-29
BR0211739A (pt) 2004-09-28
HK1067123A1 (en) 2005-04-01
EP1432683A1 (fr) 2004-06-30
CY1117051T1 (el) 2017-04-05
AR037139A1 (es) 2004-10-27
SI1432683T1 (sl) 2006-04-30
ES2334678T3 (es) 2010-03-15
HUP0401163A2 (hu) 2004-09-28
AP2004002989A0 (en) 2004-03-31
TNSN04024A1 (en) 2006-06-01
HU229563B1 (en) 2014-02-28
HK1140487A1 (en) 2010-10-15
DK1600441T3 (da) 2010-02-08
EP1600441A2 (fr) 2005-11-30
DE60206787T2 (de) 2006-07-13
NO325541B1 (no) 2008-06-16
IL153917A0 (en) 2003-07-31
HUP0401163A3 (en) 2009-04-28
ES2212759T3 (es) 2006-04-16
ECSP044973A (es) 2004-06-28
SI2157083T1 (sl) 2016-01-29
CY1109711T1 (el) 2014-08-13
CN101475524B (zh) 2012-08-29
MXPA04001069A (es) 2005-02-17
ES2212759T1 (es) 2004-08-01
EP1600441B1 (fr) 2009-12-30
EA005673B1 (ru) 2005-04-28
IL164648A (en) 2007-02-11
EP1432683B1 (fr) 2005-10-19
UA82988C2 (uk) 2008-06-10
PL216066B1 (pl) 2014-02-28
DE60234961D1 (de) 2010-02-11
NO335651B1 (no) 2015-01-19
PT2157083E (pt) 2016-01-22
KR20050111799A (ko) 2005-11-28
EP1600441A3 (fr) 2005-12-07
NZ531558A (en) 2005-12-23
IL153917A (en) 2005-11-20
NO20082330L (no) 2004-03-24
PT1600441E (pt) 2010-01-20
NZ541341A (en) 2007-02-23
EP2036890A1 (fr) 2009-03-18
CN101475524A (zh) 2009-07-08
OA12648A (en) 2006-06-16
UY27410A1 (es) 2003-03-31
JP2005504045A (ja) 2005-02-10
ITMI20011726A0 (it) 2001-08-06
ATE307114T1 (de) 2005-11-15
EP2157083A3 (fr) 2010-03-24
HK1086263A1 (en) 2006-09-15
AU2002327924B2 (en) 2008-04-24
ME01525B (fr) 2011-02-10
KR20050043992A (ko) 2005-05-11
EA200400280A1 (ru) 2004-08-26
KR100667687B1 (ko) 2007-01-12
PL369522A1 (en) 2005-05-02
DK2157083T3 (en) 2015-11-02
CN1538957A (zh) 2004-10-20
SI1600441T1 (sl) 2010-02-26
EP1432683B9 (fr) 2006-01-18
AP1766A (en) 2007-08-10
ES2555213T3 (es) 2015-12-29
EP2157083B1 (fr) 2015-09-30
HRP20040156A2 (en) 2004-08-31
HRP20040156B1 (en) 2012-03-31
MEP2908A (en) 2010-10-10
PE20030328A1 (es) 2003-05-09
AU2002327924C1 (en) 2009-12-10
ATE453624T1 (de) 2010-01-15
WO2003014084A1 (fr) 2003-02-20
CN100448847C (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
MA27133A1 (fr) Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe
SE0302760D0 (sv) New compounds
TNSN06200A1 (fr) Derives de quinoleine nouveaux
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
FR2780403B3 (fr) Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
JO2371B1 (en) 4-phenyl-pyridine derivatives
IS2863B (is) Arípíprazóllausn til gjafar um munn
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
CA2462453A1 (fr) Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
MA28093A1 (fr) Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine
NO20040881L (no) Orale antidiabetes midler.
MA27921A1 (fr) Systemes emulsifiants contenant des derives d'azetidine
CA2296637A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, son procede de preparation et compositions pharmaceutiques le contenant
DK1230236T3 (da) Forbindelse med væksthormonfrigörende egenskaber
WO2003087062A3 (fr) Composes heterocycliques, procede de preparation de ces composes et compositions pharmaceutiques les contenant, et utilisations en medecine
MA26953A1 (fr) Derives de pipérazine pontés.
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
WO2002036118A3 (fr) Derives heterocycliques utiles en tant qu'agents pharmaceutiques
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
MA27922A1 (fr) Formulations semi-solides de derives d'azetidine